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Abstract
BACKGROUND: The new trend in diagnosis of the lymph node
is sentinel node biopsy. This method has become increasingly
accepted as a minimally invasive alternative to routine axillary
dissection. Although the results of numerous studies have
shown that sentinel node biopsy can accurately determine the
axillary nodal status, the identification rates and false-negative
rates have been variable. The sentinel lymph node is defined
as the first node in the lymphatic basin that receives the primary
lymphatic flow.
MATERIAL AND METHODS: Between September 1998 and
August 2002 123 patients with primary operative breast cancer
without clinical palpable axillary lymph nodes were enrolled in
the study. There were two groups of patients according to sen-
tinel node identification technique: 51 patients (Group I) received
parenchymal, peritumoral injection of 1.0 ml of 16 MBq Tc99m-
-radiolabelled sulphur colloid and single intradermal injection
of blue-dye over the tumour. The next 72 patients (Group II)
received intradermal, periareolar one-site injection of 0.5 ml
of 16 MBq Tc99m-radiolabelled sulphur colloid and blue-dye.
RESULTS: Sentinel lymph node was found in 41 (80.4%) cases
in Group I and in 67 (93.0%) cases in Group II (p = 0.028). The
localisation of the axillary lymph node as a “hot spot” visual-
ised by lymphoscintigraphy was successful in 39/51 (76.5%)
cases in Group I and 67/72 (93.0%) in Group II, p = 0.004).
In both groups the success of sentinel node identification in the
axillary region by lymphoscintigraphy was connected with sen-
tinel lymph node finding during surgery (Group I: p < 0.001,
Group II: p < 0.001).
CONCLUSIONS: This study shows that intradermal, periareolar
one-site injection of Tc99m-radiolabelled sulphur colloid and blue-
dye is superior to peritumoral 4-sites injections Tc99m-radiola-
belled sulphur colloid and single intradermal injection of blue-
dye over the tumour in sentinel lymph node identification.
Key words: sentinel node, breast cancer, lymphoscintigraphy
Introduction
Axillary node status remains the most important prognostic
indicator of survival in breast cancer but the role of axillary lymph
node dissection is one of the most controversial areas in the man-
agement of invasive breast cancer. Between 8% and 10% of breast
tumours drain outside the axilla (internal mammary nodes, supra-
clavicular nodes) and approximately 3% of these are metastatic.
Furthermore, between 70% and 80% of patients with axillary node
dissection do not have nodes metastasis [9].
The new trend in diagnosis of the lymph node is sentinel node
biopsy. This method has become increasingly accepted as a min-
imally invasive alternative to routine axillary dissection. Although
the results of numerous studies have shown that sentinel node
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of the axillary lymph node as a “hot spot” visualised by  lymphos-
cintigraphy was successful in 39/51 (76.5) cases in Group I and in
67/72 (93.0%) in Group II, (p = 0.004).
The lymphoscintigraphy showed drainage to internal mam-
mary or supraclavicular nodes in 6 cases in Group I (14.0%) and
in 7 cases in Group II (8.8%), p = 0.443.
In both groups the success of sentinel node identification in
the axillary region by lymphoscintigraphy was connected with senti-
nel lymph node finding during surgery (Group I: p < 0.001, Group II:
p < 0.001).
The tumour localisation and tumour size in clinical assess-
ment were not connected with the sentinel lymph node identifica-
tion rate in the axillary region.
Discussion
Sentinel lymph node biopsy guided by pre-surgical lymphos-
cintigraphy, intraoperative gamma-probe and blue-dye technique
proves to be accurate with a success rate near to 95% [7].
In many reports a combination method of blue-dye and radioiso-
tope is superior to blue-dye or isotope only [3–5, 7, 8]. The site of
blue-dye and radiotracer may be intradermal [2, 5, 11], subder-
mal [1, 3, 6, 10] or peritumoral [5–7, 11, 20].
We demonstrate two different methods of sentinel lymph node
identification. One is based on peritumoral radioisotope injection
and intradermal blue-dye injection and the second on intrader-
mal, periareolar injection of radioisotope and blue-dye. In all cas-
es pre-surgical lymphoscintigraphy was performed.
The tumour size and localisation in breast quadrants did not
influence the sentinel node detection rate.
In the peritumoral radioisotope method (Group I) the sentinel node
was found in 80.4% cases v. 93.0% cases in Group II (p =  0.028).
This confirms data from published reports that dermal injection of
radioactive colloid is superior to peritumoral injection [11].
Lymphoscintigraphy defines the pattern of lymph flow and may
prevent failure or false-negative biopsies [13]. It is essential for
visualising the sentinel lymph node [12] but the failure of sentinel
visualisation in lymphoscintigraphy is not connected with the in-
traoperative gamma-probe guided or/and blue-dye success iden-
tification rate. But on the other hand the identification of the senti-
nel node in lymphoscintigraphy is connected with the high rate of
intraoperative sentinel finding [14]. Results from our study con-
firm these data: the success of sentinel node identification in the
biopsy can accurately determine the axillary nodal status, the iden-
tification rates and false-negative rates have been variable [3–5,
7, 8]. The sentinel lymph node is defined as the first node in the
lymphatic basin that receives the primary lymphatic flow.
We performed this analysis to compare two methods of senti-
nel node identification: peritumoral and subdermal, periareolar. In
both of these methods we used blue-dye and isotope techniques.
One day prior to the surgery lymphoscintigraphy was performed
in all cases.
Material and methods
Between September 1998 and August 2002 123 patients with
primary operative breast cancer without clinical palpable axillary
lymph nodes were enrolled in the study. There were two groups of
patients according to sentinel node identification technique:
51 patients (Group I) received parenchymal, peritumoral injection
of 1.0 ml of 16 MBq Tc99m-radiolabelled sulphur colloid and single
intradermal injection of blue-dye over the tumour. The next
72 patients (Group II) received intradermal, periareolar one-site
injection of 0.5 ml of 16 MBq Tc99m-radiolabelled sulphur colloid
and blue-dye. The isotope was injected one day prior to surgery.
The blue-dye marker was injected 15 min before surgical proce-
dure. The volume of isotope or blue-dye marker for one-site injec-
tion was 0.5–1.0 ml. In all cases one day before surgery lymphos-
cintigraphy was performed. During surgery the sentinel lymph node
was visualised by blue-dye technique and using the gamma-probe
guided method. The details of the technique of lymphoscintigra-
phy, isotope and blue-dye intraoperative sentinel lymph node iden-
tification methods have been previously described [17, 18].
The average age of patients in Group I was 52 years and in
Group II was 53.8 years. The median tumour size was 22.8 mm in
Group I and 22.1 mm in Group II. Most of the patients were in T1c
or T2 in TNM classification (84.3% and 83.3%, respectively). The
characteristics of patients both Group I and II are shown in Table 1.
The tumour localisation was defined according to breast quad-
rants: upper outer (UO), upper inner (UI), lower outer (LO), lower
inner (LI) and Central (C). The characteristics of tumour localisa-
tion are shown in Table 2.
Results
Sentinel lymph node was found in 41 (80.4%) cases in Group
I and in 67 (93.0%) cases in Group II (p = 0.028). The localisation
Table 1. Characteristics of patients
Group I Group II
No. of patients 51 72
Average age 52.0 53.8
Tumour size in clinical assessment 22.8 22.1
Tumour size (T grade)
T1a 0 1
T1b 1 1
T1c 15 31
T2 28 29
T0 7 10
Table 2. The tumour localisation according to breast quadrants
Quadrants Group I Group III
UO 26 31
UI 1 10
LO 1 4
LI 1 3
UO/UI 10 13
UI/LI 1 2
LO/LI 3 4
UO/LO 6 4
Central 2 1
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axillary region by lymphoscintigraphy was connected with senti-
nel lymph node finding during surgery.
One of the important roles of lymphoscintigraphy is the iden-
tification of lymph flow directions to other regions than the axillary
one [15–19]. In our study lymphoscintigraphy showed drainage
to internal mammary or supraclavicular nodes in Group I (14.0%)
and in Group II (8.8%), p = 0.443.
Conclusions
This study demonstrates that intradermal, periareolar one-site
injection of Tc99m-radiolabelled sulphur colloid and blue-dye is
superior to peritumoral 4-sites injections Tc99m-radiolabelled sul-
phur colloid and single intradermal injection of blue-dye over the
tumour in sentinel lymph node identification. Positive lymphoscin-
tigraphy (“hot spot”) is connected with the high success rate of
axillary sentinel lymph node identification.
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